Analysts Set $7 Price Target for C4 Therapeutics, Signaling 270% Upside
All covering analysts rate C4 Therapeutics stock bullish, with a consensus $7 price target reflecting a 270% upside on optimism about cemsidomide. C4T plans to launch its Phase 2 MOMENTUM trial in Q1 2026, targets initial ORR data in 2H 2027, and NDA submission by year-end 2028.
1. Analyst Confidence and Price Target
All analysts covering C4 Therapeutics maintain buy ratings with a consensus price target of $7, implying a 270.37% upside based on confidence in the efficacy of cemsidomide.
2. Clinical Development Roadmap
C4T aims to initiate its Phase 2 MOMENTUM trial in Q1 2026 for fourth-line multiple myeloma patients, expects initial ORR data in 2H 2027, and plans an NDA submission by year-end 2028; a Phase 1b combination study begins in Q2 2026 and a Phase 3 trial is slated for early 2028.
3. Promising Phase 1 Data
In its 2025 Phase 1 study, cemsidomide achieved overall response rates of 40% at a 75 µg dose and 53% at 100 µg in relapsed/refractory multiple myeloma patients, underscoring its potential as a best-in-class degrader.
4. Strategic Partnerships and Pipeline Expansion
Collaborations with Merck KGaA, Roche and Biogen support C4T’s goal to file up to three additional INDs by 2028 across its neurodegenerative and inflammation degrader programs, complementing its oncology pipeline.